Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of thymosin [beta]4 in preparation of microecological balance regulator

A technology of ecological balance and thymosin, which can be used in skin care preparations, cosmetic preparations, cosmetic preparations, etc., and can solve problems such as no research on Tβ4 folliculitis.

Active Publication Date: 2020-11-06
ACADEMY OF MILITARY MEDICAL SCI
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no research on the relationship between Tβ4 and scalp SD and folliculitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of thymosin [beta]4 in preparation of microecological balance regulator
  • Application of thymosin [beta]4 in preparation of microecological balance regulator
  • Application of thymosin [beta]4 in preparation of microecological balance regulator

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1. Cross-sectional study on microbial colony of scalp seborrheic dermatitis

[0031] 1.1 Materials and methods

[0032] 1.1.1 Group selection

[0033] A healthy adult Chinese population was selected as the research object. The inclusion criteria are as follows: (1) in good health (without other diseases, including hypertension, diabetes, chronic kidney disease and other chronic diseases, excluding scalp SD); (2) aged between 20 and 59 years old; (3) living in a long-lived city Living for more than 5 years; (4) Han population; (6) able to read and understand the test protocol and voluntarily cooperate to complete the test content, and sign a written consent form.

[0034] The exclusion criteria are as follows: (1) suffer from other skin diseases on the scalp; (2) have obvious scars on the scalp; (3) have a history of skin cancer; (4) have taken oral antibiotics, immune Inhibitors, anti-inflammatory drugs or antihistamines; (5) Use past scalp scales, anti-sebor...

Embodiment 2

[0060] Example 2. Intervention study of thymosin β4 and traditional medicine in the treatment of scalp SD

[0061] 2.1 Materials and methods

[0062] 2.1.1 Grouping and Intervention Program

[0063] Each group is expected to include 25 people, a total of 4 groups, 100 people will be included, and the final valid data will be at least 20 people / group. Group interventions were implemented in accordance with Table 2. The duration of the intervention experiment was 6 weeks. Among them, blank control groups A and B (group A is the blank control group of healthy people, and group B is the blank control group of seborrheic dermatitis) always use blank control products; scalp SD intervention group C and D (group C is seborrheic dermatitis blank control group) Dermatitis positive intervention group, group D is seborrheic dermatitis Tβ4 intervention group) use the corresponding intervention products (group C uses ketoconazole lotion, group D uses Tβ4 gel) after 4 weeks, stop using, o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of thymosin [beta]4, an active fragment thereof or a derivative thereof in preparation of a microecological balance regulator for skin microbial dysbiosis, and an application in preparation of a drug for treating diseases caused by skin microbial dysbiosis. The invention also discloses a pharmaceutical preparation containing the thymosin [beta]4, the active fragment thereof or the derivative thereof and prepared according to the application. According to the application and the pharmaceutical preparation disclosed by the invention, the clinical manifestation of scalp seborrheic dermatitis patients can be rapidly improved, the improvement of overall fungal communities and bacterial communities is remarkably superior to that of a ketoconazole group fortraditional treatment, and phenotypes and micro-ecological characteristics in the later period of drug use and the follow-up period of drug withdrawal are remarkably superior to those of the ketoconazole group.

Description

technical field [0001] The invention discloses the use of a protein in the preparation of medicines, cosmetics and / or health products, and belongs to the field of preparation of medicines, cosmetics and / or health products. Background technique [0002] Seborrheic dermatitis (Seborrheic Dermatitis, SD) is a common chronic inflammatory skin disease with recurrent features, and the prevalence rate in the adult population is 1-10%. SD tends to occur in skin areas rich in sebaceous glands such as the scalp, face, chest, and back, and is mainly manifested as bran-like or greasy desquamation, erythema, inflammatory papule, and itching. The scalp is the most commonly involved site of SD due to its physiological characteristics of thick hair, rich sweat glands and sebaceous glands, and high humidity. Scalp scaling (Dandruff) is regarded as a mild type of scalp SD. It is a skin disease limited to the scalp and characterized by scalp desquamation. It is often accompanied by itching wi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/22A61P17/00A61P31/00A61K8/84A61Q19/00A61Q17/00
CPCA61K38/2292A61K9/0014A61P17/00A61P31/00A61K8/84A61Q19/00A61Q17/005
Inventor 陈薇于蕊徐俊杰林庆斌侯利华于长明付玲房婷张军
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com